Food allergy is an adverse reaction due to a specific immune response
occurring reproducibly upon exposure to certain foods. It occurs minutes
to hours after food consumption.
Immunological mechanisms can be IgE mediated, non-IgE mediated or mixed IgE and non-IgE mediated.
It may be life-threatening and is the most common cause of anaphylaxis in children.
It should be differentiated from food intolerance in which adverse
reactions from exposure to food arise from non-immunological mechanisms.
Children and adolescents with severe peanut allergy treated with the peanut-derived oral biologic immunotherapy drug AR101 may improve their tolerance to peanut protein with reduced symptom severity, according to the phase III PALISADE* trial.
Exclusive breastfeeding for 6 months is advisable for allergy prevention, while hydrolyzed formulas (HFs) with reduced allergenicity may be considered for mothers who are unable or choose not to breastfeed, an expert recommended.
Combining an initial 16-week course of the monoclonal antibody omalizumab with oral immunotherapy (OIT) significantly and safely improves desensitization to the offending foods compared with OIT alone in children and adolescents with multiple food allergies, a new study found.
The presence of eczema or atopic dermatitis with concurrent allergic sensitization at 1 year of age was associated with an increased risk of developing asthma and food allergy in later childhood at 3 years old, according to the CHILD* study.
High free sugar intake during pregnancy was associated with a heightened risk of allergy and allergic asthma in the children, independent of their sugar intake during early childhood, according to the ALSPAC* study.
Delivery of peanut protein through the skin by means of a wearable skin patch, an approach known as epicutaneous immunotherapy, is safe and shows promise for treating peanut allergy, especially in young children, according to interim results of an ongoing study.
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.